A company called Regeneron made a medicine called Dupixent that might help people with COPD breathe better. Some smart doctors think many patients will use this medicine and it can make a lot of money for the company by 2026, even more than they thought before. Read from source...

- The article title is misleading and sensationalized. It implies that Dupixent will reach $20 billion in sales by 2026 based on a single analyst's estimate, which is not a fact or a proven result, but rather an opinion or a projection. A more accurate and less clickbaity title would be "RBC Capital Markets Analyst Sees Potential For Dupixent To Reach $20B In COPD Sales By 2026".
- The article does not provide any evidence or data to support the analyst's claim, nor does it mention any potential challenges or risks that could affect Dupixent's performance in the COPD market. It simply reports the analyst's price target and rating without questioning their validity or reasoning.
- The article relies heavily on anecdotal evidence from a survey of 31 pulmonologist physicians, who are likely to have a vested interest in promoting Dupixent as a treatment option for COPD. It does not mention how many physicians were surveyed, what criteria were used to select them, or how representative they are of the larger population of COPD patients and physicians. It also does not disclose any potential conflicts of interest that could influence the physicians' opinions or the analyst's rating.
- The article uses vague and exaggerated language to describe Dupixent's potential, such as "express excitement", "rapidity of adoption", and "higher than even our bullish expectations". It also uses unrealistic assumptions, such as assuming that 20% of the eligible COPD patients will use Dupixent in the future, without providing any basis or justification for this estimate.
- The article does not mention any alternative treatments or competitors that could pose a threat to Dupixent's market share or profitability. It also does not address any ethical or social implications of promoting such an expensive and potentially risky drug as a standard treatment option for COPD, which is a chronic and debilitating condition that affects millions of people worldwide.

Possible recommendation: buy Regeneron Pharmaceuticals (REGN) stock based on the article's analysis of Dupixent's COPD sales potential reaching $20 billion by 2026. The analyst surveyed pulmonologist physicians who were excited about the ph.III data and expect rapid adoption post-approval, leading to higher sales contributions than previous estimates. However, there are risks involved such as clinical trial results, regulatory approvals, competition, pricing pressures, and market conditions that could affect the company's performance and stock price. Therefore, investors should conduct further research and consider their own risk tolerance and financial goals before making any decisions.